M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/en; “M3” below) has announced a new joint initiative with Takeda Pharmaceuticals Company Limited (Headquarters: Tokyo, Japan; CEO: Christophe Weber; URL: https://www.takeda.com/ja-jp/; “Takeda,” below) to develop and provide disease awareness services surrounding hereditary angioedema (HAE).

M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare related information to its 300,000+ physician members in Japan, and offers marketing and clinical trial services. AskDoctors service provides healthcare related Q&A for the general public, offering immediate and accurate responses from over 1,000 enlisted experienced physicians.

HAE is a rare genetic condition that causes repeated swelling across various parts of the body including the torso, face, feet, genitals, hands, and throat\(^1,2,3\). In the case of swelling in the throat, the respiratory tract may get blocked, leading to suffocation and potentially death\(^3,4\). It is estimated that 50,000 patients suffer from HAE worldwide, and in Japan, only 450 out of an estimated 2,000 ~ 3,000 patients have been properly diagnosed\(^5\). Furthermore, it has been reported that diagnosis is said to take an average of 13.8 years\(^6\) from the initial attack in Japan, 10 years\(^7\) in the U.S., and 8.5 years\(^8\) in the EU.

This endeavor aspires towards the early diagnosis of HAE through the combination of Takeda’s disease expertise, and M3’s technological capabilities and broad platform of physicians and patients. The service will assist the general public users of AskDoctors to become aware of the possibility of HAE and to seek proper help from physicians. When users search on AskDoctors using key words that are related to HAE symptoms, a checklist available on Takeda’s “Swelling and Abdominal Pain Navi” HAE disease awareness website will be displayed to the user. The user can then fill out the checklist to determine if they are at risk of HAE, and share their answers with a physician for further guidance on AskDoctors.

In line with Takeda’s desire to provide value towards the patients and their families through the creation and improvement of the entire ecosystems surrounding rare diseases that go beyond therapy development, M3 will continue to contribute to the medical industry by addressing larger issues surrounding various diseases via 7P projects that will provide optimized solutions that capitalize on the synergies across its various services and with its partners.


8 Zanichelli et al., Allergy, Asthma & Clinical Immunology 2013, 9:29